GAVI-documents

in page functions
 

20 July 2015

Gavi Full Country Evaluation 2014 Annual Dissemination Report

This report presents findings from the 2014 Gavi Full Country Evaluations (FCE).

20 July 2015

Findings from the 2014 Gavi Full Country Evaluation - Uganda

This brief presents findings for Uganda from the 2014 Gavi Full Country Evaluation (FCE) Annual Dissemination Report.

20 July 2015

Findings from the 2014 Gavi Full Country Evaluation - Zambia

This brief presents findings for Zambia from the 2014 Gavi Full Country Evaluation (FCE) Annual Dissemination Report.

20 July 2015

Findings from the 2014 Gavi Full Country Evaluation - Bangladesh

This brief presents findings for Bangladesh from the 2014 Gavi Full Country Evaluation (FCE) Annual Dissemination Report.

20 July 2015

Findings from the 2014 Gavi Full Country Evaluation - Mozambique

This brief presents findings for Mozambique from the 2014 Gavi Full Country Evaluation (FCE) Annual Dissemination Report.

30 June 2015

FAQ - Grant management change process

The Gavi Alliance grant management change process Frequently asked questions May 2015 Overall change process 1. How was it decided that grant management changes were needed? Over recent years, through a series of consultation sessions, the Gavi Alliance Board, Programme and Policy Committee (PPC), partners, countries,

20 April 2015

How to plan and conduct a joint appraisal

This guidance is intended for country stakeholders, alliance partners and Gavi Secretariat staff involved in planning and conducting the joint appraisal. This document explains the purpose and objectives of the joint appraisal and outlines suggested steps to organize a successful appraisal process.

20 April 2015

How to develop the joint appraisal report

This document accompanies the “Joint Appraisal Report Template” (Word file) and provides guidance to the joint appraisal team on how to develop the report. The content provided in each section of this document is intended to guide the appraisal discussions to ensure the relevant range of issues is covered in the appraisal and is sufficiently addressed in the final report.

20 January 2015

Final evaluation of GAVI Alliance support to Bosnia and Herzegovina: Management Response

The Vaccine Alliance’s responses to key recommendations are outlined in the accompanying Management Action Plan.

15 January 2015

Final evaluation of GAVI Alliance support to Bosnia and Herzegovina

This report presents the lessons learnt and recommendations from an evaluation of Gavi’s support to Bosnia and Herzegovina and its transition after funding ended. The evaluation was conducted by the Curatio International Foundation in 2014.

15 January 2015

EAC assessment of the Evaluation of the GAVI Alliance Co-financing Policy

Gavi, the Vaccine Alliance Board Evaluation Advisory Committee (EAC) assessment of the quality and usefulness of the Norwegian Institute of Public Health’s "Evaluation of the Gavi Alliance Co-‐financing Policy".

22 December 2014

Gavi and Ebola - FAQ

Gavi and Ebola - Frequently asked questions.

03 December 2014

HPV vaccines - FAQs

Frequently asked question for Human papillomavirus (HPV) vaccines.

03 December 2014

Pneumo and Rota - FAQs

Frequently asked question for Pneumococcal and rotavirus vaccines.

03 December 2014

Men A - FAQs

Frequently asked question for Meningococcal A Conjugate vaccine (Men A).

03 December 2014

IPV - FAQs

Frequently asked question for Inactivated Polio Vaccine (IPV).

03 December 2014

MR vaccines - FAQs

Frequently asked question for Measles-rubella (MR) vaccines.

03 December 2014

YF - FAQs

Frequently asked question for Yellow Fever (YF) vaccines.

28 November 2014

Annex C : IPV Programme Timeline of Activities

Application materials for Inactivated Polio Vaccine (IPV): Timeline of Activities.

28 November 2014

HSS Proposal Form

Application materials for Health system strengthening support – Proposal Form.

27 November 2014

HPV Demonstration Programme Budget and Financing

Application materials for HPV vaccination demonstration programme: Budget and Financing

27 November 2014

HPV Demonstration Programme Timeline

Application materials for HPV vaccination demonstration programme: Timeline

05 November 2014

Gavi meningoccal vaccine support guidelines 2015

Gavi Meningoccal vaccine guidelines outlining requirements and information to support application submission in 2015.

05 November 2014

Gavi human papillomavirus vaccine support for national introduction guidelines 2015.

HPV vaccine national guidelines outlining requirements and information to support application submission in 2015.

05 November 2014

Gavi pneumoccocal vaccine support guidelines 2015

Gavi pneumococcal vaccine guidelines outlining requirements and information to support application submission in 2015.

05 November 2014

Gavi General Guidelines NVS and HSS 2015

General guidelines for Gavi NVS and HSS support, including information on requirements and processes to support application submission in 2015.

05 November 2014

Gavi HSS guidelines 2015

Gavi HSS guidelines, including information on requirements to support application submission in 2015

05 November 2014

Gavi inactivated polio vaccine (IPV) support guidelines 2015

Gavi IPV guidelines outlining requirements and information to support application submission in 2015.

05 November 2014

Gavi measles second dose and measles-rubella vaccine support guidelines 2015

Gavi MCV2 and MR vaccine guidelines outlining requirements and information to support application submission in 2015.

05 November 2014

Gavi human papillomavirus for demonstration programme guidelines 2015

HPV vaccine demo guidelines outlining requirements and information to support application submission in 2015.

05 November 2014

Gavi Japanese encephalitis vaccine support guidelines 2015

Gavi JE vaccine guidelines outlining requirements and information to support application submission in 2015.

05 November 2014

Gavi rotavirus vaccine support guidelines 2015

Gavi rotavirus vaccine guidelines outlining requirements and information to support application submission in 2015.

05 November 2014

Gavi yellow fever vaccine support guidelines 2015

Gavi Yellow Fever vaccine guidelines outlining requirements and information to support application submission in 2015.

18 August 2014

GAVI HSS Grant Categorisation 2014

This table is intended to provide ideas of HSS activities to applicants and to allow GAVI to analyse its HSS support by type of grants.

03 July 2014

Process evaluation of Pneumococcal Vaccine Introduction – GAVI Alliance Response

Process evaluation of Pneumococcal Vaccine Introduction – GAVI Alliance Response.

03 July 2014

Process evaluation report of Pneumococcal Vaccine Introduction in Mozambique, Uganda and Zambia

Process evaluation report of Pneumococcal Vaccine Introduction in Mozambique, Uganda and Zambia.

01 July 2014

GNI per capita 2013

Gross national income per capita 2013.

30 June 2014

Key info on IPV support: dose allocation and VIG amounts calculations

Additional information on GAVI support for IPV.

31 March 2014

GAVI FCE Annual Progress Report

This report is the first annual progress report for the Full Country Evaluations project. It summarises work done in 2013 and evaluation activities to be taken forward in 2014.

31 March 2014

HSS Country ceilings

Country ceilings and maximum annual amounts for budgeting for GAVI Health Systems Strengthening (HSS) grant applications.

10 March 2014

Delivering results in HSS information sheet

Information sheet about measuring results for health system performance and improving data quality.

10 March 2014

Guidance on GAVI HSS approach and application process

Health system strengthening approach information sheet.

10 March 2014

Performance Based Funding information sheet

Information sheet about GAVI’s HSS Performance Based Funding.

10 March 2014

Human Papillomavirus vaccines information sheet

Human Papillomavirus vaccines information sheet.

10 March 2014

Japanese Encephalitis vaccines FAQ

Japanese Encephalitis vaccines Frequently Asked Questions.

14 February 2014

Overview of the public consultation on supply chain strategy

In July 2013 the GAVI Alliance held a public consultation to seek feedback from global and country stakeholders on a list of supply chain challenges and an emerging strategy framework to address those challenges. The consultation helped us map out and prioritise the activities needed to help strengthen immunization supply chain practices.

28 November 2013

Final VIS analysis 2013: Rabies

Rabies Vaccine Investment Strategy November 2013 - Background document.

28 November 2013

Final VIS analysis 2013: Cholera

Cholera Vaccine investment strategy November 2013 - Background document.

28 November 2013

Final VIS analysis 2013: Yellow Fever

Yellow fever Vaccine investment strategy November 2013 - Background document.

28 November 2013

Summary consultations phase II [French]

VIS Phase II Consultation 2013.

28 November 2013

Summary consultations phase II

VIS Phase II Consultation 2013.

28 November 2013

Final VIS analysis 2013: Malaria

Malaria Vaccine investment strategy November 2013 - Background document.

28 November 2013

Final VIS analysis 2013: Maternal Influenza

Influenza Vaccine investment strategy November 2013 - Background document.

22 November 2013

VIS Independent Expert Committee

Independent Expert Committee for the Vaccine Investment Strategy.

20 November 2013

FAQ - Civil Society Access to GAVI Pricing for Vaccines

1 Civil society access to GAVI pricing for vaccines Frequently asked questions September 2013 1. Does GAVI support the delivery of immunisation services by civil society organisations? GAVI recognises the key role that civil society organisations (CSOs) play in the national immunisation programmes of many countries. 2.

24 October 2013

Definition of performance indicators for GAVI strategy 2011-2015

This GAVI Alliance Board paper, approved at the December 2010 Board meeting in Rwanda, lists goal-level indicators to monitor progress against GAVI's 2011-15 strategy.

11 October 2013

VIS prioritisation methodology

VIS phase I: vaccine and disease parameters assessed 1 Phase I Indicator Health impact Impact on child mortality U5 future deaths averted, 2015 – 2030 U5 future deaths averted per 100,000 vaccinated population Impact on overall mortality Total future deaths averted, 2015 – 2030 Total future deaths averted per 100,000 v

10 July 2013

Vaccine Investment Strategy 2013 Phase I - Vaccine Scorecards

VIS 2013 PHASE I 1. Procurement cost includes vaccine, syringe, safety box, and freight 2. Scoring based on cost per future death averted Cholera Phase I Scorecard Modelled scenario: periodic campaigns every 3 years targeting high risk 1-<15 year olds Category VIS Criteria Phase I Indicator Phase I Evaluation Health im

14 June 2013

Frequently asked questions about Gavi's co-financing

Frequently asked questions about co-financing.

07 June 2013

GAVI Business Plan 2013-2014: deliverables and activities

Strategic objective PO Programme objective Interim deliverable (2013) Interim deliverable (2014) Programme deliverables (2015) 2.3. Strengthen civil society engagement in the health sector 2.3.1 Promote active engagement of Civil Society Organisations (CSOs) At least 50% of countries, supported by partners, have active

29 May 2013

GAVI Business Plan 2013-2014: Background narrative

The GAVI Alliance Business Plan aims to support GAVI’s mission to save children’s lives and protect people’s health by improving access to immunisation in poor countries.

04 April 2013

GAVI-Government of China Hepatitis B vaccination programme - Evaluation Report

Evaluation of GAVI-Government of GAVI-Government of China Hepatitis B vaccination programme (2013, Abt Associates).

04 April 2013

GAVI-Government of China Hepatitis B vaccination programme - Management Response

The GAVI Secretariat’s management response to the evaluation of GAVI-Government of China Hepatitis B vaccination programme (2012, Abt Associates).

26 March 2013

Request form for emergency response

As outlined in the GAVI policy on fragility and immunisation, GAVI will provide one-off flexibilities in order to help protect immunisation systems and existing GAVI support in countries experiencing time-limited emergencies. This form is developed to assist countries in such emergency circumstances wanting to apply for these flexibilities.

22 March 2013

CSO Implementation and Results Framework

The GAVI Board has decided that HSS will be the single window for GAVI cash grants. GAVI support for CSOs will be part of a country Health Systems Strengthening (HSS) proposal to improve immunisation outcomes. The document presents why and how GAVI works with and supports CSOs in programme implementation.

18 March 2013

GAVI Gender Policy Evaluation Report with Annexes

EVALUATION OF GAVI GENDER POLICY FINAL REPORT 14 December 2012 Submitted to: GAVI Alliance 2, Chemin des Mines 1211, Geneva 2 Switzerland Submitted by: ICF Macro, Inc. 11785 Beltsville Drive, Suite 300 Calverton, MD 20705 USAi TABLE OF CONTENTS Table of Contents i Acronyms and Abbreviations iii Executive Summary iv Key

18 March 2013

GAVI Gender Policy Recommendations Report

EVALUATION OF GAVI GENDER POLICY KEY RECOMMENDATIONS 14 December 2012 Submitted to: GAVI Alliance 2, Chemin des Mines 1211, Geneva 2 Switzerland Submitted by: ICF Macro, Inc. 11785 Beltsville Drive, Suite 300 Calverton, MD 20705 USA1 INTRODUCTION The GAVI Alliance public-private partnership brings together key stakehol

18 March 2013

GAVI Gender Policy Evaluation Management Action Plan

MANAGEMENT ACTION PLAN – EVALUATION OF THE GAVI ALLIANCE GENDER POLICY Date: 28 February 2013 1 Theme Recommendation Management Action Timeline/Responsibility Rationale, Design and Planning 1 Revision to gender policy: update rationale, strategic directions and commitments GAVI should commence a Gender Policy revision

06 March 2013

AMC Process and Design Evaluation Full Report

1 The Advance Market Commitment for Pneumococcal Vaccines Process and Design Evaluation Full Report February 15, 2013 Contents Preface ..................................................................................................................................................... 3 Acronyms and Abbreviations ......

06 March 2013

AMC Process and Design Evaluation Mgt Response

Page 1 of 2 GAVI Secretariat Management Response to the Process and Design Evaluation of the Pilot Advance Market Commitment for Pneumococcal Vaccines Advance Market Commitments (AMCs) for vaccines aim to encourage the development and production of affordable vaccines tailored to the needs of developing countries. Foll

06 March 2013

AMC Process and Design Evaluation Appendix Feb 2013

The Advance Market Commitment for Pneumococcal Vaccines Process and Design Evaluation Appendix February 15, 2013 Contents Appendix ............................................................................................................................................ 2 Appendix I. Timelines and inputs to design pro

24 September 2012

GAVI CSO evaluation_Ethiopia Country Report

GAVI ALLIANCE EVALUATION OF GAVI SUPPORT TO CIVIL SOCIETY ORGANISATIONS 17 January 2012 COUNTRY EVALUATION REPORT -ETHIOPIA Prepared by: Cambridge Economic Policy Associates LLP ii CONTENTS Acronyms and abbreviations .............................................................................................. iii Exec

24 September 2012

GAVI CSO evaluation_Pakistan Country Report

GAVI ALLIANCE EVALUATION OF GAVI SUPPORT TO CIVIL SOCIETY ORGANISATIONS 17 January 2012 COUNTRY EVALUATION REPORT -PAKISTAN Prepared by: Anita Zaidi with specific inputs from Ayesha Khan and support from: Cambridge Economic Policy Associates LLP ii CONTENTS Acronyms and abbreviations ...................................

24 September 2012

GAVI CSO evaluation_DRC Country Report

ŀ GAVI ALLIANCE EVALUATION OF GAVI SUPPORT TO CIVIL SOCIETY ORGANISATIONS 17 January 2012 COUNTRY EVALUATION REPORT -DRC Prepared by: Eliot Putnam, CEPA Associate and Cambridge Economic Policy Associates LLP ii CONTENTS Acronyms and abbreviations .........................................................................

24 September 2012

GAVI CSO Evaluation_CEPA Recommendations Paper

ŀ GAVI ALLIANCE EVALUATION OF GAVI SUPPORT TO CSOS 3 February 2012 RECOMMENDATIONS PAPER Prepared by: CEPA LLP CONTENTS Acronyms and abbreviations ................................................................................................ i 1. Introduction ..........................................................

24 September 2012

GAVI CSO evaluation_CEPA Evaluation Report Annexes

ŀ GAVI ALLIANCE EVALUATION OF GAVI SUPPORT TO CSOS 17 January 2012 EVALUATION REPORT (ANNEXES) Prepared by: CEPA LLP CONTENTS Annex 1: Glossary.................................................................................................................. 1 Annex 2: Bibliography and data sources .....................

24 September 2012

GAVI CSO evaluation_Afghanistan Country Report

GAVI ALLIANCE EVALUATION OF GAVI SUPPORT TO CIVIL SOCIETY ORGANISATIONS 17 January 2011 COUNTRY EVALUATION REPORT -AFGHANISTAN Prepared by: Drs. Kayhan Natiq & Essa Tawfiq with support from: Cambridge Economic Policy Associates LLP ii CONTENTS Acronyms and abbreviations .................................................

24 September 2012

Management response to 2011 CSO Evaluation

1 EVALUATION OF GAVI SUPPORT TO CSOs Management Response – September 2012 Theme Recommendation Management Response Timeline/Responsibility Structure of GAVI CSO Support Focus of the support 1. GAVI CSO support should be restructured as a ‘single funding stream’ rather than two separate types of support. The focus shoul

24 September 2012

GAVI CSO evaluation_Indonesia Country Report

GAVI ALLIANCE EVALUATION OF GAVI SUPPORT TO CIVIL SOCIETY ORGANISATIONS 17 January 2012 COUNTRY EVALUATION REPORT -INDONESIA Prepared by: Cambridge Economic Policy Associates LLP ii CONTENTS Acronyms and abbreviations .............................................................................................. iii Exe

24 September 2012

GAVI CSO evaluation_CEPA Evaluation Main Report

ŀ GAVI ALLIANCE EVALUATION OF GAVI SUPPORT TO CSOS 17 January 2012 EVALUATION REPORT Prepared by: CEPA LLP CONTENTS Acronyms and abbreviations ................................................................................................ i Executive summary ............................................................

12 September 2012

HSS Policy Timeline

Health System Strengthening (HSS) Policies and Major Decisions at GAVI Timeline and Overview.

05 July 2012

Accelerated Vaccine Introduction Project review: annexes

Annexes to report presenting the findings and lessons learnt from a review of the Accelerated Vaccine Introduction (AVI) Project. The review period spans from February to June 2012.

05 July 2012

Accelerated Vaccine Introduction Project review: final report

This report presents the findings and lessons learnt from a review of the Accelerated Vaccine Introduction (AVI) Project undertaken by Cambridge Economic Policy Associates (CEPA) for the GAVI Alliance. The review period spans from February to June 2012.

21 December 2011

2010 Work Plan Report

The 2010 Work Plan Report highlights the 2010 progress under each output of the 2007-2010 work plan.

01 July 2011

IFFI evaluation: IFFIm donor response

Donors feel that the report presents valuable information about the goal effectiveness, costs effectiveness, and impacts in terms of lives saved by IFFIm. The evaluation shows, while highlighting constraints (size), lost opportunities (frontloading too early) and potential challenges (sustainability), that IFFIm has so far achieved impacts beyond those specifically targeted for immunisation.

01 July 2011

IFFIm evaluation: key messages

The International Financing Facility for Immunisation (IFFIm) concept is proven. IFFIm has allowed donor countries to make binding long-term commitments and convert these future cash flows into immediately available funds through the financial markets at a cost very close to that achieved by the World Bank. 

01 July 2011

IFFIm evaluation: executive summary

This evaluation was commissioned by the GAVI Secretariat, on behalf of the IFFIm Board, to assess the extent to which the IFFIm has been an effective financing mechanism to raise money for immunisation and health systems in GAVI eligible countries.

01 July 2011

IFFIm evaluation: The World Bank response

The World Bank has reviewed an evaluation report of the International Finance Facility for Immunisation (IFFIm) prepared by HLSP and dated June 2011. The World Bank provides services to IFFIm under the Treasury Management Agreement and this report substantially reviews those activities in the context of IFFIm’s overall performance as a financing vehicle.

01 July 2011

IFFIm evaluation: IFFIm Board response

This paper provides a response to the IFFIm Evaluation by the IFFIm Board of Directors. 

28 June 2011

IFFIm evaluation: GAVI Secretariat response

GAVI Secretariat response to IFFIm evaluation which assessed both IFFIm’s efficacy as a financing mechanism, as well as the extent to which IFFIm has contributed to enhancing GAVI’s impact on immunisation and health.

21 June 2011

IFFIm evaluation: full report

The IFFIm evaluation assesses the extent to which IFFIm is an effective and efficient instrument to attract long-term, predictable donor funds and to frontload money to finance GAVI Alliance support for immunisation and health systems.

20 April 2011

IFFIm evaluation: annexes

1 . A. 21 February 2011 Evaluation of the International Finance Facility for Immunisation (IFFIm) ANNEXES April 2011 HLSP, Sea Containers House, 20 Upper Ground, London SE1 9LZ, United Kingdom T +44 (0)20 7803 4545 F +44 (0)20 7803 4502, W www.hlsp.org Evaluation of the International Finance Facility for Immunisation (

03 February 2011

Second GAVI Evaluation 2006-2010

This evaluation seeks to answer two high-level questions: to what extent has the GAVI Alliance met its four Strategic Goals (SGs); and to what extent has the GAVI Alliance added value at the global and country levels, over and above what would have been accomplished without the Alliance?

01 February 2011

Kenya : pneumonia and pneumococcal disease

Childhood pneumonia is a major public health issue in Kenya; it is the second leading cause of death among children under five. Thanks to the AMC, two vaccines (PCV10 and PCV13) against pneumococcal disease have been approved so far for introduction in GAVI-eligible countries.

01 December 2010

GAVI Alliance monitoring and evaluation framework and strategy 2011-2015

The Monitoring and Evaluation Framework and Strategy is designed to contribute to meeting the GAVI Alliance’s diverse information needs, including those related to internal business processes, support to countries and overall effectiveness, efficiency and impact.

01 December 2010

GAVI Alliance Strategy and Business Plan 2011-2015

This GAVI Alliance Business Plan 2011-2015 describes the actions to be undertaken to achieve the 2011-2015 Strategy, while also laying out the context and challenges for the coming years.

29 October 2010

Baseline Study for pneumococcal vaccine AMC

The goal of the AMC baseline study was to establish the environment prior to the AMC with baseline estimates for a selection of indicators related to the objectives of the AMC and to model counterfactual scenarios to ascertain the potential impact of the AMC vis-a-vis traditional financial and procurement strategies.

01 October 2010

Evaluation Advisory Committee report to the Board on the Second GAVI Evaluation

The Committee's overall assessment is that this is a credible and useful evaluation. The evaluation has yielded a number of important insights that will prove useful to the Board and Alliance as it prepares for and then implements its new strategy for the 2011-15 period.

13 September 2010

Supporting Paper 5: Progress against recommendations made by the Phase I Evaluation

Table presenting the key recommendations made by the Phase 1 evaluation and the GAVI Secretariat response. In addition, CEPA has interviewed Secretariat colleagues to understand progress made to date against these recommendations, which is noted in the final column labelled ‘implementation progress’.

13 September 2010

Supporting Paper 4.1: Bangladesh country study report

The report provides contextual information on Bangladesh’s health and immunisation sector, and assesses the results and value add of GAVI programs in the country from the country stakeholders’ perspective.

 



close icon

modal window here